Popeyes Chicken, covert surveillance and alleged rotting meat
Susan Krashinsky Robertson, The Globe's retail business reporter, breaks down the allegations, recounts the corporate surveillance and explains what it could mean for the chicken you're eating.
Questions? Comments? Ideas? E-mail us at thedecibel@globeandmail.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
20 minutes ago
- Globe and Mail
Q2 Announces Dual Listing on NYSE Texas
Q2 Holdings, Inc. (NYSE: QTWO), a leading provider of digital transformation solutions for financial services, today announced the dual listing of its common stock on NYSE Texas, the newly launched fully electronic equities exchange based in Dallas, Texas. Q2 will continue to maintain its primary listing on the New York Stock exchange and trade under the symbol QTWO on both exchanges. The listing will be effective on August 15, 2025. 'Texas has always been home for Q2,' said Q2 Chairman and CEO Matt Flake. 'Our dual listing on NYSE Texas is a natural extension of our commitment to this community, where so many of our team members, customers, and partners live and work. As a Founding Member of NYSE Texas, we are proud to play a role in shaping the future of Texas-based innovation and fueling economic growth.' 'As a company founded and headquartered in Austin, Q2's mission is deeply rooted in the spirit of Texas innovation,' said Chris Taylor, Chief Development Officer, NYSE Group. 'We are excited to welcome the company to our NYSE Texas community of Founding Members.' Founded in 2004 in Austin, Texas, Q2 is a global technology provider powering modern banking experiences for financial institutions and fintechs. With its global headquarters in Texas, Q2 continues to support financial institutions across the region and beyond, helping them serve millions of consumers and small businesses. 'Our mission is to build strong and diverse communities by strengthening their financial institutions,' said Flake. 'That work starts at home. Our Texas-based customers rely on Q2 to help them compete, grow, and serve their communities in new ways.' Q2's impact in Texas extends beyond business. Through Q2 Spark—Q2's corporate social responsibility program—team members give their time, talent and expertise to impact their neighbors, customers and one another through volunteerism and community service efforts. In partnership with Austin FC, Q2 contributes to its mission through the Austin FC Dream Starter Competition and Q-mmunity Gives grant program, which create impact and promote entrepreneurship in Central Texas and beyond. To learn more about Q2, visit About Q2 Holdings, Inc. Q2 is a leading provider of digital transformation solutions for financial services, serving banks, credit unions, alternative finance companies, and fintechs in the U.S. and internationally. Q2 enables its financial institution and fintech customers to provide comprehensive, data-driven digital engagement solutions for consumers, small businesses and corporate clients. Headquartered in Austin, Texas, Q2 has offices worldwide and is publicly traded on the NYSE under the stock symbol QTWO. To learn more, please visit Follow us on LinkedIn and X to stay up to date.
Globe and Mail
20 minutes ago
- Globe and Mail
Abbott Taps Growing TMVR Market With Tendyne System
Abbott Laboratories ABT recently received Food and Drug Administration ('FDA') approval for its Tendyne transcatheter mitral valve replacement (TMVR) system. The Tendyne system replaces mitral valves that are not functioning properly due to severe mitral annular calcification (MAC). The Tendyne system expands the company's comprehensive Structural Heart portfolio. The rising prevalence of mitral valve diseases, growing preferences for minimally invasive procedures and expanding geriatric population has driven the adoption of TMVR system. Investors are eyeing this fast-growing market, which is projected to witness a compound annual growth rate of 20% from 2025 to 2030 (Per a Medi-Tech Insights report). MAC stiffens the structure of the mitral valve and can lead to mitral regurgitation or stenosis that disrupts the heart's ability to pump blood effectively. The complex nature of this mitral valve disease and patients' specific needs and health conditions can pose challenges for surgical correction. The Tendyne system offers an alternative, minimally invasive way to replace the valve of patients with severe MAC who are at high risk for open-heart surgery. The innovative and unique design of the Tendyne system and the valve's availability in multiple sizes allow it to adapt to a range of patient anatomies. The self-expanding valve is delivered through a small incision in the chest and then advanced into the heart to replace the mitral valve. The valve is fully repositionable and retrievable during implantation, allowing for the best possible outcome for people requiring a valve replacement. Offerings By ABT's Peers in the Structural Heart Field Edwards Lifesciences EW makes significant investments in the development of transcatheter heart valve repair and replacement technologies designed to treat mitral and tricuspid valve diseases. The company's PASCAL Precision system addresses the needs of patients with mitral or tricuspid regurgitation through leaflet approximation. The EVOQUE system is the world's first transcatheter tricuspid valve replacement therapy to receive regulatory approval. It addresses tricuspid valve regurgitation by replacing the native valve with a bioprosthetic valve. In addition, SAPIEN M3 transcatheter mitral valve replacement system is designed specifically for patients with symptomatic mitral regurgitation. Medtronic 's MDT Structural Heart & Aortic division offers therapies for heart valve disorders and aortic disease. Key products include the CoreValve family (Evolut PRO, PRO+, FX, FX+ TAVR systems), surgical valve replacement and repair solutions (tissue and mechanical), blood-handling systems, surgical ablation technologies, and positioning/stabilization tools. The company also provides endovascular stent grafts and accessories like the Endurant II Stent Graft System (abdominal aortic aneurysms), Valiant Captivia Thoracic Stent Graft System (thoracic repair) and Heli-FX EndoAnchor System. ABT Price Performance In the past year, Abbott shares have surged 19.2%, outperforming the industry's 6.2% growth. The S&P 500 composite grew 17.8% in the same period. Image Source: Zacks Investment Research Discounted Valuation ABT currently trades at a forward 12-month Price-to-Sales (P/S) of 4.87X compared with the industry average of 5.56X. Image Source: Zacks Investment Research ABT Stock Estimate Trend In the past 30 days, Tempus AI's EPS estimate has moved south 0.2% for 2025. Image Source: Zacks Investment Research ABT stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report This article originally published on Zacks Investment Research (
CTV News
20 minutes ago
- CTV News
Charges laid in Hamilton crash that left mother and her 10-year-old child dead
Video A 24-year-old man has been charged in a crash in Hamilton last month that left a mother and her 10-year-old child dead.
